Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 8:59 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 6,188 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Medication Group Clear all

Conditions: Hunter Syndrome
Interventions: Control, Idursulfase IT (1 mg), Idursulfase IT (10 mg), Idursulfase IT (30 mg); Other · Drug
Lead sponsor: Shire; Industry
Eligibility: 3 Years to 18 Years · Male only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Parkinson's Disease
Interventions: Gold Nanocrystals; Drug
Lead sponsor: Clene Nanomedicine; Industry
Eligibility: 30 Years to 80 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Primary Pulmonary Hypertension
Interventions: LIQ861 Inhaled Treprostinil; Drug
Lead sponsor: Liquidia Technologies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 38
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 30 more

Conditions: Strep Pharyngitis, Pneumonia
Interventions: Integrated Clinical Prediction Rule (iCPR); Other
Lead sponsor: Northwell Health; Other
Eligibility: Not listed
Enrollment: 168 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Hypertension
Interventions: lisinopril, carvedilol controlled release formulation; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 654 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 151
States / cities: Anniston, Alabama • Birmingham, Alabama • Haleyville, Alabama + 131 more

Conditions: Candidemia, Mycoses, Fungal Infection, Fungemia, Invasive Candidiasis
Interventions: CD101, Caspofungin, Fluconazole, intravenous placebo, oral placebo; Drug
Lead sponsor: Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 16
States / cities: Birmingham, Alabama • Davis, California • Miami, Florida + 12 more

Conditions: Chronic Pain
Interventions: Spinal Cord Stimulator Set to Minimal/No Stimulation Setting, Usual Care, Positron Emission Tomography / Magnetic Resonance Imaging; Other · Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Substance-Related Disorders
Interventions: Motivational Enhancement Therapy; Behavioral
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 12 Years to 21 Years
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy Volunteers
Interventions: REGN2222; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 2
States / cities: Daytona Beach, Florida • Evansville, Indiana

Conditions: Pleural Effusions, Chronic, Congestive Heart Failure, Shortness of Breath
Interventions: tunneled pleural catheter; Device
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Opioid Use, Spine Fusion
Interventions: Spinal Fusion Preoperative Opioid Taper, Non-taper Control; Behavioral · Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Redwood City, California

Conditions: HIV-infection/Aids
Interventions: Cognitive-behavioral HIV/STD risk reduction; Behavioral
Lead sponsor: Mississippi State University; Other
Eligibility: 13 Years to 18 Years · Female only
Enrollment: 333 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Columbia, Mississippi

Conditions: Pain, Burns
Interventions: VR-based Pain Alleviation Tool (VR-PAT); Other
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Osteoporosis, Osteoporosis, Postmenopausal
Interventions: Parathyroid Hormone-related Protein, Placebo; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 50 Years to 75 Years · Female only
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Glaucoma, Open Angle
Interventions: brimonidine, timolol; Drug
Lead sponsor: Chicago Center for Vision Research; Other
Eligibility: 30 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2004
U.S. locations: 12
States / cities: Little Rock, Arkansas • Gainesville, Florida • Palm Beach Gardens, Florida + 7 more

Conditions: Non-cystic Fibrosis Bronchiectasis
Interventions: Galvokimig, Placebo; Biological
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 6
States / cities: Newport Beach, California • Brandon, Florida • Plantation, Florida + 3 more

Conditions: Obstructive Sleep Apnea
Interventions: Surgical OSA treatment, Positive Airway Pressure Therapy; Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Cataract Extraction
Interventions: Moxifloxacin 0.5% ophthalmic solution, Besifloxacin 0.6% ophthalmic suspension; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hypogonadal Males
Interventions: ABT-SLV361, placebo; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years to 80 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Fort Myers, Florida

Conditions: Chemotherapy-Induced Nausea and Vomiting
Interventions: Netupitant and Palonosetron, Palonosetron, Dexamethasone; Drug
Lead sponsor: Helsinn Healthcare SA; Industry
Eligibility: 18 Years and older
Enrollment: 1,455 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 28
States / cities: Anniston, Alabama • Muscle Shoals, Alabama • Hot Springs, Arkansas + 24 more

Conditions: Atrial Fibrillation, Obesity, Anticoagulants
Interventions: Apixaban; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 107,383 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Stimulant Use Disorder, Cocaine Use Disorder, Methamphetamine Use Disorder
Interventions: LDART, Psychoeducational booklet; Device · Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Bipolar Disorder, Mixed Mania, Treatment-Resistant Mania
Interventions: Allopurinol, Placebo; Drug · Other
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Heavy Menstrual Bleeding, Fibroid Uterus
Interventions: Groups 1 and 2 myomectomy and uterine artery embolization, respectively, are surgical/procedure, Elagolix Oral Product; Other · Drug
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Search by objective public record fields.

A Safety and Dose Ranging Study of Idursulfase (Intrathecal) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Hunter Syndrome Who Have Central Nervous System Involvement and Are Receiving Treatment With Elaprase®

31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Parkinson's Disease

Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil

Evidence Based Decision Making: Integrating Clinical Prediction Rules

The COREG And Lisinopril Combination Therapy In Hypertensive Subjects (COSMOS) Trial

CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension

From Nerve to Brain: Toward a Mechanistic Understanding of Spinal Cord Stimulation in Human Subjects

Medical Office Intervention for Adolescent Drug Use

Study of the Blood Concentrations of Two Formulations of REGN2222 in Healthy Subjects

Tunneled Pleural Catheters for Refractory Effusions Attributed to Congestive Heart Failure (TREAT-CHF) Trial

Does Preoperative Pain Medication Management Influence Surgical Outcomes in Spinal Fusion

Healthy Teen Girls: HIV Risk Reduction

VR for Pain Management During Adult Burn Dressing Change

3-Week Parathyroid Hormone-related Protein (PTHrP) Dose Escalation Study in Post-Menopausal Women

Study of Medical Treatment of Low-Pressure (Normal Tension) Glaucoma

A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Adult Study Participants With Non-Cystic Fibrosis Bronchiectasis

Measuring Effectiveness in Sleep Apnea Surgery

Study of Ocular Penetration of Topically Administered Fluoroquinolones

Study of the Safety, Tolerability and Pharmacokinetics of Testosterone Undecanoate in Hypogonadal Males.

An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting

Effectiveness And Safety Of Oral Anticoagulants Among Obese Patients With Non-Valvular A-Fib In VA Patients With Medicare

LDART for Stimulant Use Disorder

Allopurinol Add-on Treatment for Refractory Mania

Myomectomy vs Uterine Artery Embolization vs GnRh Antagonist for AUB-L